Quince Therapeutics Completes Acquisition of EryDel S.p.A.

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)—- $QNCX–Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company developing an innovative drug delivery technology that leverages a patient’s own biology to deliver rare disease therapeutics, announced the successful completion of its acquisition of EryDel S.p.A., a privately-held, late-stage biotech company. Quince’s newly acquired Phase…
Click here to view original post